𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impact of surveillance on survival after laryngeal cancer in the medicare population

✍ Scribed by David O. Francis; Bevan Yueh; Ernest A. Weymuller Jr.; Albert L. Merati


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
184 KB
Volume
119
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objectives/Hypothesis:

Routine surveillance is advocated to detect recurrent disease after treatment for laryngeal cancer. This aim of this study was to determine the 1‐ and 5‐year postrecurrence mortality for laryngeal cancers and evaluate whether more intensive surveillance improved survival.

Study Design:

Retrospective cohort study.

Methods:

Patients with recurrent cancers (1992–1999) were identified in a national cancer clinical database. Multivariate analysis was used to evaluate the effect of surveillance on postrecurrence survival.

Results:

Of 2,121 recurrent cancers identified, 913 were laryngeal. Patients with laryngeal cancer recurrence had 27% (P = .001) and 22% (P = .007) better odds of 1‐ and 5‐year survival than other sites. The 1‐ and 5‐year postrecurrence survival rates for laryngeal cancer patients were 72.4% and 41.3%, respectively. Glottic cancer cases had the best postrecurrence life expectancy. Multivariate regression revealed that clinical surveillance intensity had no independent impact on their survival (P < .05). However, patients with recurrent glottic cancer seen in surveillance had 23% improved odds of survival (P = .037).

Conclusions:

More frequent surveillance visits was not associated with a survival advantage in the overall population. Patients with glottic cancer had a postrecurrence survival advantage if seen during the surveillance period. Laryngeal cancer patients had better postrecurrence survival than other head and neck sites. Laryngoscope, 2009


πŸ“œ SIMILAR VOLUMES


A population-based study evaluating the
✍ Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 183 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH

The impact of new chemotherapeutic and h
✍ Stephen K. Chia; Caroline H. Speers; Yulia D'yachkova; Anna Kang; Suzanne Malfai πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. Over the past decade, a number of new therapeutic agents have become available in the treatment of metastatic breast cancer (MBC). This study characterized the use and assessed the impact on survival of population‐based access to new agents for the treatment of MBC. ##